Search results
May 23, 2024 · Ashvattha Therapeutics is a biopharmaceutical company developing precision nanomedicines for ophthalmology, neurology, and inflammatory diseases. The nanomedicines use hydroxyl dendrimer technology to target activated cells in regions of inflammation.
People also ask
Who is Ashvattha Therapeutics?
What programs does Ashvattha offer?
Could Ashvattha's hydroxyl dendrimer solve VEGF toxicity problems?
Ashvattha Therapeutics is a biotech company developing nanomedicines for inflammatory and neurodegenerative diseases. Learn about their pipeline products, including D-4517.2 for wet AMD and DME, OP-801 for ALS, and OP-101 for COVID-19.
Feb 22, 2024 · Ashvattha Therapeutics is a clinical-stage company developing nanomedicine therapeutics that target activated cells in regions of inflammation. It has enrolled the first patient in a Phase 1/2 study of 18F-OP-801, a PET imaging agent that can detect neuroinflammation in ALS, AD, MS and PD.
Sep 7, 2022 · Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology,...
Aug 1, 2022 · Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology,...
Jun 15, 2021 · OP-101 is a novel hydroxyl dendrimer therapeutic that targets hyperinflammation and neuronal injury in severe COVID-19 patients. Interim data show improved survival, reduced inflammation and NfL levels, and no adverse events with OP-101.